Stock ALZCUR ALZECURE PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Market Closed - Nasdaq Stockholm
Other stock markets
 10:29:40 2024-05-31 am EDT 		5-day change 1st Jan Change
2.04 SEK -2.39% Intraday chart for AlzeCure Pharma AB -7.27% -34.41%
May. 14 AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors CI
May. 13 AlzeCure Pharma AB Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member
Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors
Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application
AlzeCure Pharma AB Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application
AlzeCure Pharma publishes prospectus
AlzeCure publishes its interim report for January – March 2024
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).
AlzeCure Pharma publishes its Annual Report for 2023
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
AlzeCure to partake in Redeye Theme, Alzheimer on March 21
AlzeCure to partake in Redeye Theme: Alzheimer on March 21
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer's conference
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer's
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALZCUR Stock
  4. News AlzeCure Pharma AB
  5. Other languages